Gabapentin Capsule
Product Images NDC 70518-4706

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 70518-4706). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Gabapentin 100 mg capsule label showing quantity of 30 capsules. Label includes NDC 70518-4706-00 and manufacturer Rising Pharma, Inc. in Allendale, NJ. Instructions advise usual dosage per insert and storage between 20-25°C with permitted excursions. Labeler Remedy Repack Inc., Indiana, PA, contact provided.*

FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 01)

Chemical structure of gabapentin showing its molecular framework with a cyclohexane ring attached to an aminomethyl and acetic acid group.*

FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 02)

A line graph comparing mean pain scores over an 8-week period for placebo and gabapentin 3600 mg/day. The x-axis represents weeks from baseline to week 8, and the y-axis shows mean pain scores from 0 to 10. The graph includes a 4-week dose titration period and a 4-week fixed dose period. Gabapentin shows a decline in pain scores over time compared to placebo.*

FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 03)

A line graph depicting mean pain scores over a 7-week period comparing placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day. The x-axis represents time in weeks, including a 3-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores ranging from 0 to 10. Gabapentin groups show decreasing pain scores over time compared to placebo.*

FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 04)

A bar chart titled "Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies" comparing placebo (PBO) and gabapentin (GBP) doses in two studies. Study 1 shows 12% response for PBO and 29% for GBP 3600. Study 2 shows 14% for PBO and 32% and 34% for GBP 1800 and GBP 2400, respectively, with significance levels noted (p < 0.01 and p < 0.001).*

FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 05)

A scatter plot chart showing percentage difference versus daily dose (mg) with data points labeled from three studies (Study a, Study b, Study c). The x-axis represents daily dose ranging approximately from 600 mg to 1800 mg, and the y-axis shows difference in percentage ranging from 2% to 22%. Data points are identified by distinct markers for each study group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.